

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**





Figure 1

Figure 2







Figure 3

Figure 4






Figure 5




Figure 6

2679 TALKFHIQSPVPAPEPGKNTGDHPVLYMGSRQATGDMGVSLRNQKVHWYRLGKAGPTTLSIDENIGEQFAAVS IDR
 2757 A5G-1 A5G-2 A5G-3 A5G-4 A5G-5 A5G-6 A5G-7 A5G-8 A5G-9 A5G-10
 2758 TLQFGHMSVTVEKQMVKHEIKGDTVAPGSEGLLNLHPDPDVFYVGGYPSNFTPPEPLRFPGLGCIEMETLNNEEVVSLY
 2834 A5G-11 A5G-12 A5G-13 A5G-14 A5G-15 A5G-16 A5G-17 A5G-18
 2835 NPEQTPMHDATAVDKPCARSKATGDPWLTDGSYLDGSGFARISPEKQFSNTKRFQELRLVSYNGIIFFLKQESQFLCL
 2912 A5G-19 A5G-20 A5G-21 A5G-22 A5G-23 A5G-24 A5G-25 A5G-26 A5G-27 A5G-28
 2913 AVQEGTLVLFYDPGSGLKKADPLQPPQALTAASKAIQVFLLAGNRKRVLVRVERATVFSVDQDNMLEMADAYYLGGVP
 2980 A5G-29 A5G-30 A5G-31 A5G-32 A5G-33 A5G-34 A5G-35 A5G-36 A5G-37 A5G-38
 2981 PEQLPLSLRQLFPSSGGSVRGCIKGKIKALGKYVDLKRNLTTGISPCTADLLVGRMTFHGHGFLPLALPDVAPITEVV
 3058 A5G-39 A5G-40 A5G-41 A5G-42 A5G-43 A5G-44 A5G-45 A5G-46 A5G-47
 3059 YSGPGFRGTQDNNNLLYYRTSPDGPYQVSLREGHVTLRFMNQEVEVETQRVFADGAPHYVAFYSNVTGVWLYVDDQLQLVK
 3146 A5G-48 A5G-49 A5G-50 A5G-51 A5G-52 A5G-53 A5G-54 A5G-55 A5G-56
 3147 SHERTTPMLQLQPEEPSRLLLGGLPVSGTFHNPGCISNVFVQRLRGPQRVPDLHQNMGSVNVSVGCTPAQLIETSRA
 3224 A5G-57 A5G-58 A5G-59 A5G-60 A5G-61 A5G-62 A5G-63 A5G-64 A5G-65 A5G-66
 3225 TAQKVSRRSRQPSQDLACTTPWLPGTIQDAYQPGGPLPSYLQPGVGISPSHRNRLHLSMLVRPHAAQGLLLSTAPMSG
 3302 A5G-67 A5G-68 A5G-69 A5G-70 A5G-71 A5G-72 A5G-73 A5G-74 A5G-75
 3303 RSPSLVLFNHHGPVAQTEGPGPRLQVQSRQHSRAGQWHRVSVRWGMQQIQLVVVDGSQTWSQKALHHRVPRAEPPQY
 3380 A5G-76 A5G-77 A5G-78 A5G-79 A5G-80 A5G-81 A5G-82 A5G-83 A5G-84 A5G-85
 3381 TLSVGGLPASSYSSKLPVSVGSGCLKKLQLDKQPLRTPTQMVGVTPCVSGPLEDGLFFPGSEGVVTLLELPKAKMPYV
 3458 A5G-86 A5G-87 A5G-88 A5G-89 A5G-90 A5G-91 A5G-92 A5G-93
 3459 SLELEMPLAAAGLIFHLGQALATPYMQLKVLTEQVLLQANDGAGEFSTWVTPKLCGDRWHRVAVIMGRDTLRLLEVD
 3536 A5G-94 A5G-95 A5G-96 A5G-97 A5G-98 A5G-99 A5G-100 A5G-101 A5G-102
 3537 TQSNHTTGRLPESLAGSPALLHLGSLPKSSTARPELPAYRGCLRKLLINGAPVNVTASVQIQGAVGMRGCPSTLALS
 3614 A5G-103 A5G-104 A5G-105 A5G-106 A5G-107 A5G-108 A5G-109 A5G-110 A5G-111
 3615 KQGKALTQHAKPSVSPLLH
 3635 A5G-112 A5G-113

Figure 7

PEPTIDES	Laminin Chain and Amino Acid Sequence Number	Amino Acid Sequence	% Disruption/ Disassembly of Fibrillar Aβ (Aβ:Peptide Molar Ratio of 1:6)
AG73	Alpha-1 chain; residues 2719-2730	RKRLQVQLSIRT	46 % (S; p < 0.01)***
A3	Alpha-3 chain; residues 2243-2254	KPRLQFSLDIQT	23 % (S; p < 0.01)
A5	Alpha-5 chain; residues 3275-3286	RNRLHLSMLVRP	22 % (S; p < 0.01)
C-16	Gamma-1 chain; residues 139-150	KAFDITYVRLKF	28 % (S; p < 0.01)***
LAM-L	Alpha-1 chain; residues 2097-2108	AASIKVAVSADR	24 % (S; p < 0.01)
A-13	Alpha-1 chain; residues 97-109	RQVFQVAYIIKA	30 % (S; p < 0.01)***
HA3G45	Alpha-3 chain; residues 1173-1184	ASFGFQTFQPSG	21 % (S; p < 0.05)
HA3G47	Alpha-3 chain; residues 1189-2000	HQTWTRNLQVTL	28 % (S; p < 0.01)***
HA3G58	Alpha-3 chain; residues 1276-1287	ISNVFVQRLSLS	32 % (S; p < 0.01)***
HA3G67	Alpha-3 chain; residues 1342-1353	ASPPSVKVWQDA	25 % (S; p < 0.01)***
HA3G71	Alpha-3 chain; residues 1379-1390	FKLPQELLKPRS	23 % (S; p < 0.05)
HA3G74	Alpha-3 chain; residues 1402-1414	RGLVFHTGKNSF	32 % (S; p < 0.01)***
HA3G75	Alpha-3 chain; residues 1411-1422	KNSFMALYLSKG	24 % (S; p < 0.01)
HA3G76	Alpha-3 chain; residues 1418-1429	YLSKGRLVFAKG	26 % (S; p < 0.01)***
HA3G79	Alpha-3 chain; residues 1444-1455	NDGKWHVTVFGH	27 % (S; p < 0.01)***
HA3G83	Alpha-3 chain; residues 1477-1487	GNSTISIRAPVY	33 % (S; p < 0.01)***
A4G31	Alpha-4 chain; residues 1101-1112	LHVFYDFGFNSG	23 % (S; p < 0.01)
A4G82	Alpha-4 chain; residues 1513-1524	TLFLAHGRLVFM	30 % (S; p < 0.01)***
A5G15	Alpha-5 chain; residues 2792-2803	HPDDFVFYVGGY	30 % (S; p < 0.01)***
A5G35	Alpha-5 chain; residues 2950-2961	VLVRVERATVFS	20 % (S; p < 0.05)
A5G46	Alpha-5 chain; residues 3043-3054	FLPLALPDVAPI	21 % (S; p < 0.05)
A5G56	Alpha-5 chain; residues 3135-3146	WLYVDDQLQLVK	27 % (S; p < 0.01)***
A5G71	Alpha-5 chain; residues 3259-3270	GPLPSYLYQFVGI	22 % (S; p < 0.05)
A5G80	Alpha-5 chain; residues 3329-3340	VQSRQHSRAGQW	25 % (S; p < 0.01)***
A5G81	Alpha-5 chain; residues 3337-3348	AGQWHRVSVRWG	41 % (S; p < 0.01)***
A5G82	Alpha-5 chain; residues 3345-3356	VRWGMQQIQLVV	29 % (S; p < 0.01)***
A5G84	Alpha-5 chain; residues 3361-3372	TWSQKALHHRVP	27 % (S; p < 0.01)***
A5G101	Alpha-5 chain; residues 3516-3527	DGRWHRVAVIMG	39 % (S; p < 0.01)***
A5G109	Alpha-5 chain; residues 3587-3598	APVNVTASVQIQ	32 % (S; p < 0.01)***
A5G110	Alpha-5 chain; residues 3594-3605	SVQIQGAVGMRG	23 % (S; p < 0.05)

*** Selected for Further Testing

Figure 8

Figure 9





Figure 10



PTI-	Structure	Formula	MW
DP-001 D-AG73 or D-A1 A1-chain 2719-2730	Arg-Lys-Arg-Lue-Gln-Val-Gln-Leu-Ser-Ile-Arg-Thr	C ₆₄ H ₁₂₀ N ₂₄ O ₁₇	1497.82
DP-002 D-A13 A1-chain 97-109	Arg-Gln-Val-Phe-Gln-Val-Ala-Tyr-Ile-Ile-Lys-Ala	C ₇₄ H ₁₂₁ N ₁₉ O ₁₇	1548.90
DP-003 D-HA3G76 A3-chain 1418-1429	Tyr-Leu-Ser-Lys-Gly-Arg-Leu-Val-Phe-Ala-Leu-Gly	C ₆₃ H ₁₀₂ N ₁₆ O ₁₅	1323.61
DP-004 D-A4G82 A4-chain 1513-1524	Thr-Leu-Phe-Leu-Ala-His-Gly-Arg-Leu-Val-Phe-Met	C ₆₇ H ₁₀₅ N ₁₇ O ₁₄ S	1404.75
DP-005 D-A5G81 A5-chain 3337-3348	Ala-Gly-Gln-Trp-His-Arg-Val-Ser-Val-Arg-Trp-Gly	C ₆₅ H ₉₅ N ₂₃ O ₁₅	1438.62
DP-006 D-A5G101 A5-chain 3516-3527	Asp-Gly-Arg-Trp-His-Arg-Val-Ala-Val-Ile-Met-Gly	C ₆₁ H ₉₇ N ₂₁ O ₁₅ S	1396.65
DP-007 D-HA3G47 A3-chain 1189-2000	His-Gln-Thr-Trp-Thr-Arg-Asn-Leu-Gln-Val-Thr-Leu	C ₆₆ H ₁₀₅ N ₂₁ O ₁₉	1496.70
DP-008 D-HA3G58 A3-chain 1276-1287	Ile-Ser-Asn-Val-Phe-Val-Gln-Arg-Leu-Ser-Leu-Ser	C ₆₁ H ₁₀₃ N ₁₇ O ₁₈	1362.60

Fig. 12a

PTI-	Structure	Formula	MW
DP-009 D-HA3G74 A3-chain 1402-1414	Arg-Gly-Leu-Val-Phe-His-Thr-Gly-Thr-Lys-Asn-Ser-Phe	C ₆₆ H ₁₀₂ N ₂₀ O ₁₈	1463.67
DP-010 D-HA3G83 A3-chain 1477-1487	Gly-Asn-Ser-Thr-Ile-Ser-Ile-Arg-Ala-Pro-Val-Tyr	C ₅₆ H ₉₂ N ₁₆ O ₁₈	1277.45
DP-011 D-A5G82 A5-chain 3345-3356	Val-Arg-Trp-Gly-Met-Gln-Gln-Ile-Gln-Leu-Val-Val	C ₆₆ H ₁₀₉ N ₁₉ O ₁₆ S	1456.78
DP-012 D-A5G109 A3-chain 1444-1455	Ala-Pro-Val-Asn-Val-Thr-Ala-Ser-Val-Gln-Ile-Gln	C ₅₃ H ₉₁ N ₁₅ O ₁₈	1226.40
DP-013 D-rAG73 or D-rA1 A1-chain r2719-2730 or 2730-2719	Thr-Arg-Ile-Ser-Leu-Gln-Val-Gln-Leu-Arg-Lys-Arg	C ₆₄ H ₁₂₀ N ₂₄ O ₁₇	1497.82
DP-014 D-rA13 A1-chain r92-109 or 109-92	Ala-Lys-Ile-Ile-Ile-Tyr-Ala-Val-Gln-Phe-Val-Gln-Arg	C ₇₄ H ₁₂₁ N ₁₉ O ₁₇	1547.92
DP-015 D-rHA3G76 A3-chain r1418-1429 or 1429-1418	Gly-Leu-Ala-Phe-Val-Leu-Arg-Gly-Lys-Ser-Leu-Tyr	C ₆₃ H ₁₀₂ N ₁₆ O ₁₅	1323.61
DP-016 D-rA4G82 A4-chain r1513-1524 or 1524-1513	Met-Phe-Val-Leu-Arg-Gly-His-Ala-Leu-Phe-Leu-Thr	C ₆₇ H ₁₀₅ N ₁₇ O ₁₄ S	1404.75

Fig. 1ab









PTI-	Structure	Formula	MW
DP-017 D-rA5G81 A5-chain r3337-3348 or 3348-3337	Gly-Trp-Arg-Val-Ser-Val-Arg-His-Trp-Gln-Gly-Ala 	C ₆₅ H ₉₅ N ₂₃ O ₁₅	1438.62
DP-018 D-rA5G101 A5-chain r3516-3527 or 3527-3516	Gly-Met-Ile-Val-Ala-Val-Arg-His-Trp-Arg-Gly-Asp 	C ₆₁ H ₉₇ N ₂₁ O ₁₅ S	1396.65
LP-019 AG73 or A1 A1-chain 2719-2730	Arg-Lys-Arg-Lue-Gln-Val-Gln-Leu-Ser-Ile-Arg-Thr 	C ₆₄ H ₁₂₀ N ₂₄ O ₁₇	1497.82
LP-020 A13 A1-chain 92-109	Arg-Gln-Val-Phe-Gln-Val-Ala-Tyr-Ile-Ile-Ile-Lys-Ala 	C ₇₄ H ₁₂₁ N ₁₉ O ₁₇	1548.90
LP-021 HA3G76 A3-chain 1418-1429	Tyr-Leu-Ser-Lys-Gly-Arg-Leu-Val-Phe-Ala-Leu-Gly 	C ₆₃ H ₁₀₂ N ₁₆ O ₁₅	1323.61
LP-022 A4G82 A4-chain 1513-1524	Thr-Leu-Phe-Phe-Met-Arg-Leu-Val-His-Ala-Leu-Gly 	C ₆₇ H ₁₀₅ N ₁₇ O ₁₄ S	1404.75
LP-023 A5G81 A5-chain 3337-3348	Ala-Gly-Gln-Trp-His-Arg-Val-Ser-Val-Arg-Trp-Gly 	C ₆₅ H ₉₅ N ₂₃ O ₁₅	1438.62
LP-024 A5G101 A5-chain 3516-3527	Asp-Gly-Arg-Trp-His-Arg-Val-Ala-Val-Ile-Met-Gly 	C ₆₁ H ₉₇ N ₂₁ O ₁₅ S	1396.65

Fig. 12c









PTI-	Structure	Formula	MW
LP-025 β-sheet breaker or iAB5	Leu-Pro-Phe-Phe-Asp 	C ₃₃ H ₄₃ N ₅ O ₈	637.74
DP-026 Trc'n 5;1-7	Ala-Gly-Gln-Trp-His-Arg-Val 	C ₃₈ H ₅₆ N ₁₄ O ₉	852.95
DP-027 Trc'n 5;2-8	Gly-Gln-Trp-His-Arg-Val-Ser 	C ₃₈ H ₅₆ N ₁₄ O ₁₀	868.95
DP-028 Trc'n 5;3-9	Gln-Trp-His-Arg-Val-Ser-Val 	C ₄₁ H ₆₂ N ₁₄ O ₁₀	911.04
DP-029 Trc'n 5;4-10	Trp-His-Arg-Val-Ser-Val-Arg 	C ₄₂ H ₆₆ N ₁₆ O ₉	939.09
DP-030 Trc'n 5;5-11	His-Arg-Val-Ser-Val-Arg-Trp 	C ₄₂ H ₆₆ N ₁₆ O ₉	939.09
DP-031 Trc'n 5;6-12	Arg-Val-Ser-Val-Arg-Trp-Gly 	C ₃₈ H ₆₂ N ₁₄ O ₉	859.00
DP-032 Trc'n 6;1-7	Asp-Gly-Arg-Trp-His-Arg-Val 	C ₄₀ H ₆₀ N ₁₆ O ₁₀	925.02

Fig. 12d









PTI-	Structure	Formula	MW
DP-033 Trc'n 6;2-8	Gly-Arg-Trp-His-Arg-Val-Ala 	C ₃₉ H ₆₀ N ₁₆ O ₈	881.01
DP-034 Trc'n 6;3-9	Arg-Trp-His-Arg-Val-Ala-Val 	C ₄₂ H ₆₆ N ₁₆ O ₈	923.09
DP-035 Trc'n 6;4-10	Trp-His-Arg-Val-Ala-Val-Ile 	C ₄₂ H ₆₅ N ₁₃ O ₈	880.07
DP-036 Trc'n 6;5-11	His-Arg-Val-Ala-Val-Ile-Met 	C ₃₆ H ₆₄ N ₁₂ O ₈ S	825.05
DP-037 Trc'n 6;6-12	Arg-Val-Ala-Val-Ile-Met-Gly 	C ₃₂ H ₆₀ N ₁₀ O ₈ S	744.96
DP-038 Trc'n 4;1-7	Thr-Leu-Phe-Leu-Ala-His-Gly 	C ₃₆ H ₅₅ N ₉ O ₉	757.89
DP-039 Trc'n 4;2-8	Leu-Phe-Leu-Ala-His-Gly-Arg 	C ₃₈ H ₆₀ N ₁₂ O ₈	812.97
DP-040 Trc'n 4;3-9	Phe-Leu-Ala-His-Gly-Arg-Leu 	C ₃₈ H ₆₀ N ₁₂ O ₈	812.98


Fig. 12e

PTI-		Structure	Formula	MW
DP-041	Trc'n 4;4-10	Leu-Ala-His-Gly-Arg-Leu-Val	C ₃₄ H ₆₀ N ₁₂ O ₈	764.93
DP-042	Trc'n 4;5-11	Ala-His-Gly-Arg-Leu-Val-Phe	C ₃₇ H ₅₈ N ₁₂ O ₈	798.95
DP-043	Trc'n 4;6-12	His-Gly-Arg-Leu-Val-Phe-Met	C ₃₉ H ₆₂ N ₁₂ O ₈ S	859.07
DP-044	Trc'n 15;1-7	Gly-Leu-Ala-Phe-Val-Leu-Arg	C ₃₇ H ₆₂ N ₁₀ O ₈	774.97
DP-045	Trc'n 15;2-8	Leu-Ala-Phe-Val-Leu-Arg-Gly	C ₃₇ H ₆₂ N ₁₀ O ₈	774.97
DP-046	Trc'n 15;3-9	Ala-Phe-Val-Leu-Arg-Gly-Lys	C ₃₇ H ₆₃ N ₁₁ O ₈	789.98
DP-047	Trc'n 15;4-10	Phe-Val-Leu-Arg-Gly-Lys-Ser	C ₃₇ H ₆₃ N ₁₁ O ₉	805.98
DP-048	Trc'n 15;5-11	Val-Leu-Arg-Gly-Lys-Ser-Leu	C ₃₄ H ₆₅ N ₁₁ O ₉	771.96
DP-049	Trc'n 15;6-2	Leu-Arg-Gly-Lys-Ser-Leu-Tyr	C ₃₈ H ₆₅ N ₁₁ O ₁₀	836.01

Fig. 12f


In Vitro Screening of Laminin Peptides

Fig. 13




In Vitro Screening of Laminin Peptides

Congo Red Binding of Ab42 +/- Laminin Peptides




In Vitro Screening of Laminin Peptides




۱۵۱



In Vitro Screening of Laminin Peptides

Congo Red Binding of A β 42









Legend:

$\text{A}\beta 42$ Only —

0.1 mg/ml —





PTI-compound only 0.2 mg/ml —

$\text{A}\beta 42 + \text{PTI-compound}$ 1:2 wt/wt —






Legend:

- A β 42 Only —
- 0.1 mg/ml —
- 0.2 mg/ml —
- A β 42 + PTI-compound 1:2 wt/wt —




Legend:





- $\text{A}\beta 42$ Only —
- PTI-compound only 0.2 mg/ml —
- $\text{A}\beta 42 + \text{PTI-compound}$ 1:2 wt/wt —



Legend:

- A β 42 Only —
- 0.1 mg/ml —
- PTI-compound only
- 0.2 mg/ml —
- 1:2 wt/wt —







Legend:

- $\text{A}\beta 42$ Only —
- PTI-compound only —
- 0.2 mg/ml —
- 0.1 mg/ml —
- $\text{A}\beta 42 + \text{PTI-compound}$ 1:2 wt/wt —


PTI-DP-011



PTI-DP-012




PTI-DP-011

**Legend:**


- $\text{A}\beta 42$ Only —
- PTI-compound only —
- 0.2 mg/ml —
- 0.1 mg/ml —
- $\text{A}\beta 42 + \text{PTI-compound}$ 1:2 wt/wt —

D Wavelength [nm]




ε₂₁ PTI


MRE ($\times 10^{-3}$ deg $\text{cm}^2 \text{dmol}^{-1}$)




MRE ($\times 10^{-3}$ deg $\text{cm}^2 \text{dmol}^{-1}$)



MRE ($\times 10^{-3}$ deg $\text{cm}^2 \text{dmol}^{-1}$)



MRE ($\times 10^{-3}$ deg $\text{cm}^2 \text{dmol}^{-1}$)



PTI-DP-013




PTI-DP-013





Legend:

A β 42 Only
0.1 mg/ml

PTI-compound only
0.2 mg/ml

A β 42 + PTI-compound
1:2 wt/wt





Legend:

PTI-compound only —


$\text{A}\beta 42$ Only —

0.2 mg/ml —


0.1 mg/ml —

$\text{A}\beta 42 + \text{PTI-compound}$
1:2 wt/wt —

C



D



CD#34